Summary
Soybean lipoxygenase inhibition has been proposed as an in vitro biochemical model for the antiinflammatory action of certain drugs used in the treatment of ulcerative colitis. In an extension of a recent study which showed that therapeutically active compounds, such as sulphasalazine and its colonic metabolite 5-aminosalicylic acid were soybean lipoxygenase inhibitors, it has now been shown that N-acetylaminosalicylic acid, the principal metabolite of 5-aminosalicylic acid, also inhibits soybean lipoxygenase in a dose dependent and noncompetitive manner (Ki 3.0×10−8M, IC50 250 µM). Sulphapyridine, the other major metabolite of sulphasalazine, which has been demonstrated to be inactive in the treatment of ulcerative colitis, did not inhibit the lipoxygenase activity. The findings further support the hypothesis that only the therapeutically active compounds are soybean lipoxygenase inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hermanowicz A, Nawarska Z (1981) Chemotaxis and random migration of polymorphonuclear leukocytes in ulcerative colitis examined by the agarose method. Scand J Gastroenterol 16: 961–966
Stein DT, Gray GM, Gregory PB, Anderson M, Goodwin DA, MacDougall JR (1983) Location and activity of ulcerative and Crohn's colitis by indium 111 leukocyte scan. Gastroenterology 84: 388–393
Azad Khan AK, Truelove SC, Aronson JR (1982) The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol 13: 523–528
Molin L, Stendhal O (1974) The effect of sulphasalazine and its active compounds on human polymorphonuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand 206: 451–457
Sircar JC, Schwender CF, Carethers ME (1983) Inhibition of soybean lipoxygenase by sulphasalazine and 5 aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem. Pharmacol 32: 170–172
Hawkey CJ, Truelove SC (1983) Inhibition of prostaglandin synthetase in human rectal mucosa. Gut 24: 213–217
Bray MA, Ford-Hutchinson AW, Smith MJH (1981) Leukotriene B4: an inflammatory mediator in vivo. Prostaglandins 22: 213–222
Klickstein LB, Shapleigh CH, Goetzl EJ (1980) Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluids and tissue in rheumatoid arthritis and spondylarthritis. J Clin Invest 66: 1166–1170
Borgeat P, Fruteau de Laclos P, Maclouf J (1983) New concepts in the modulation of leukotriene synthesis. Biochem Pharmacol 92: 381–387
Kingston WP (1981) 15-Lipoxygenase: a rapid, sensitive assay for lipoxygenase inhibitors. Br J Pharmacol 74: 919
Willoughby CP, Piris J, Truelove SC (1980) The effect of topical N-acetyl-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol 15: 715–719
Azad Khan AK, Piris J, Truelove SC (1977) An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2: 240–245
Axelrod B, Cheesbrough TH, Laakso S (1981) Lipoxygenase from soybeans. Methods in enzymology, vol 71. Academic Press, New York, p 441–451
Tappel AL, Lundsberg O, Boyer PD (1953) Effect of temperature and antioxidants upon the lipoxidase-catalyzed oxidation of sodium linoleate. Arch Biochem Biophys 42: 293–294
Lowry OH, Rosebrough NG, Farr AL, Randall RJ (1951) Determination of protein with the folin reagent. J Biol Chem 193: 265–275
Baker BR (1967) Design of active site directed irreversible enzyme inhibitors. Wiley, New York, pp 202–204
Dissanayake AS, Truelove SC (1973) A controlled therapeutic trial of long term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrine) Gut 14: 923–925
Hees von PAM, Bakker JH, van Tongeren JHM (1980) Effect of sulphapyridine, 5 aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 21: 632–635
Rachmilewitz D, Treves AJ, Ligumski M, Sharon P, Zifroni A, Karmeli F (1982) Possible role of prostanoids as mediators in the pathogenesis of inflammatory bowel disease. In: Rachmileitz (ed) Developments in gastroenterology, vol 3. Inflammatory bowel diseases. Martinus Nijholt, Hague Boston London, pp 161–173
Hoult JRS, Moore PK (1982) Prostaglandins and the mode of action of sulphasalazine in ulcerative colitis: two opposing viewpoints. Ibidem, pp 174–189
Casey FB, Appleby BJ, Buck DC (1981) Selective inhibition of the lipoxygenase metabolic pathway of arachidonic acid by the SRA-A antagonist FPL 55 7R. Prostaglandins 25: 1–11
Gilat T, Ratan J, Rosen P, Peled P (1979) Prostaglandins and ulcerative colitis. Gastroenterology 76: 1083
Rampton DS, Sladen GE (1981) Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins 21: 417–425
Campieri M, Lanfranchi GA, Bazzocchi G, Brignola C, Corazza G, Cortini C et al. (1978) Salicylate other than 5-aminosalicylic acid ineffective in ulcerative colitis. Lancet 2: 993
De Groot JJMC, Garssen GJ, Vliegendthart JFG, Boldingh J (1973) The detection of linoleic acid radicals in the anaerobic reaction of lipoxygenase. Biochim Biophys Acta 326: 279–284
Hoult JRS, Page H (1981) 5-aminosalicylic acid, a cofactor for colonic prostacyclin synthesis? Lancet 2: 255
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allgayer, H., Eisenburg, J. & Paumgartner, G. Soybean lipoxygenase inhibition: Studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol 26, 449–451 (1984). https://doi.org/10.1007/BF00542139
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542139